Skip to main content
S

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Filings indexed 155 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-08 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2026-04-22 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-06 English
Press Release
Regulatory Filings
2026-04-03 English
General Updates
Regulatory Filings
2026-04-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.